Novartis
NEWS
Swiss pharma giant Novartis could be on its way to securing regulatory approval for its secondary progressive multiple sclerosis (SPMS) treatment siponimod.
The use of multiple, potentially costly, drugs during combination therapy all contributes to the high costs in oncology. DO you know why does immunotherapy cost so much?
Boston Pharma went on a buying binge, licensing a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.
Immuno-oncology comes pretty close to being a miracle cure for certain types of cancer. But it’s not perfect, and a recently reported isolated case demonstrates that there are risks.
Technology has had a massive impact on basically every area of life. One very important part of medical research that technology has been having a noticeable impact on is clinical trials.
Janssen Biotech, a Johnson & Johnson company, informed Aduro Biotech that it was terminating its research and license deals related to Aduro’s Listeria treatment for cancers.
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Emgality (galcanezumab-gnlm) for migraine prevention.
Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.
JOBS
IN THE PRESS